Editor’s Note: Cannabis is still a new industry, filled with profit potential that isn’t always easy to see unless you have the time to keep up with every single development. That’s why the National Institute for Cannabis Investors shares its findings – so you don’t have to dig through search engines and dense research to find the opportunity. And this just-released update from them gives you two companies leading the way in a process that’s yielding more reliable, safe cannabis products.
Cannabidiol (CBD) has been the poster child of the cannabis-based medicine movement for years. CBD is the cannabis plant’s primary non-psychoactive compound.
In a highly concentrated form, it makes an incredibly effective pharmaceutical – one that could even prove to be a powerful weapon in the fight against COVID-19.
And it’s emerging as a lucrative market in its own right – one that’s making folks like you a lot of money already.
Each of these compounds, and all their possible combinations, represents a veritable ocean of new possibilities for medical researchers.
For you, that means an endless pool of new profit opportunities just waiting to be unlocked…
A New Way to Make Reliable and Safe Cannabis Products
The process that’s key to unlocking those profits is biosynthesis. At its core, biosynthesis is a naturally occurring process that uses simple chemical compounds to create more complex compounds. This, of course, is an oversimplification of an unbelievably sophisticated process.
Cannabis companies can use biosynthesis to turn microbes such as yeast into tiny cannabinoid factories.
Once the genome of, say, brewer’s yeast has been altered to manufacture a cannabinoid like the rare cannabigerol (CBG) instead of alcohol, these trace cannabinoids can be manufactured very cheaply in vast quantities.
By using biosynthesis to manufacture cannabinoids, you also get a much more consistent, reliable, and safe end product – something that is important for all cannabis consumers, but particularly when it comes to pharmaceutical-grade products.
Looking to the future, that type of safety and consistency could make biosynthesis an appealing option for receiving U.S. Food and Drug Administration (FDA) approval, as the FDA has expressed concern over those factors when it comes to cannabis-based products.
Today, there are cannabis companies out there already taking advantage of biosynthesis, and even more that could benefit from it down the road.
Using Biosynthesis to Unlock Profits
InMed Pharmaceuticals Inc. (OTC: IMLFF), for example, is leading the way in testing the therapeutic properties of the rare cannabinoid, cannabinol…